Seyed Alireza Alhosseini

Posted on Aug 2

🧬 Beyond Prompt Engineering: Building a Cognitive-Augmented AI Architecture for Drug Discovery

#ai #drug #python #machinelearning

From Prompt-to-Drug to Closed-Loop Scientific Intelligence

What if the biggest limitation in AI-driven drug discovery is not the size of the model?

What if the real bottleneck is how intelligence is orchestrated?

Modern generative AI can generate molecules, predict molecular properties, analyze biological data, and assist with clinical development.

But generating a plausible molecule is not the same as discovering a drug.

A real drug-discovery system must connect:

Biology → Targets → Molecules → Experiments → Evidence → Clinical Decisions

This raises a deeper architectural question:

Can we build an AI system that does not simply answer scientific questions, but continuously generates, challenges, tests, and improves scientific hypotheses?

This is the central idea behind Cognitive-Augmented AI for Drug Discovery.

🔥 The Problem: AI Can Generate — But Can It Discover?

A conventional LLM workflow is simple:

Prompt
  ↓
LLM
  ↓
Answer

This architecture works remarkably well for language.

Drug discovery is different.

A real discovery program involves multiple scientific disciplines, heterogeneous datasets, specialized computational engines, physical experiments, regulatory constraints, and enormous uncertainty.

A more realistic architecture looks like:

Disease Intelligence
        ↓
Target Hypothesis
        ↓
Molecular Design
        ↓
Virtual Validation
        ↓
Experimental Validation
        ↓
Evidence
        ↓
Model Update
        ↺

The challenge is therefore not simply better generation.

It is scientific orchestration.

🧠 From Prompt Engineering to Cognitive Orchestration

The proposed Cognitive-Augmented architecture uses structured prompting and multi-agent reasoning as an orchestration layer, rather than treating prompts as a substitute for scientific infrastructure.

The original framework combines approaches such as:

Mega-Prompt
RACE
RISEN
Persona-Based prompting
CREATE
Chain-of-Thought
Few-Shot prompting
CRAFT
RTF
Iterative Refinement

But these techniques should not be confused with the drug-discovery engines themselves.

The distinction is fundamental:

Prompt Engineering ≠ Drug Discovery

Instead:

Prompt Engineering → Cognitive Orchestration → Scientific Engines → Experimental Validation

This separation makes the architecture both more realistic and more testable.

🏗️ The Seven-Layer Architecture

The next generation of AI drug discovery can be conceptualized as seven interconnected layers.

01 — Disease Intelligence

The system integrates:

multi-omics
genomic data
proteomics
biomedical literature
clinical information
disease-associated pathways

The objective is not simply to retrieve information.

It is to construct a disease-level representation.

02 — Target Hypothesis Engine

The system generates and ranks potential therapeutic targets.

Instead of asking:

“Which protein is associated with the disease?”

the system asks:

“Which intervention point has the strongest causal, biological, therapeutic and translational justification?”

This is where AI-assisted target discovery becomes fundamentally different from simple information retrieval.

03 — Generative Molecular Design

Once a target hypothesis has sufficient support, generative chemistry systems can explore candidate molecules.

The optimization problem becomes multi-dimensional:

Affinity
   +
Selectivity
   +
ADMET
   +
PK
   +
Toxicity
   +
Novelty
   +
Synthesizability

The objective is therefore not:

Generate the molecule with the best binding score.

It is:

Generate the molecule with the best overall scientific profile under competing constraints.

04 — Multi-Objective Validation

A promising candidate must survive multiple computational filters.

For example:

Dimension	Question
Affinity	Does it bind the target?
Selectivity	Does it avoid undesirable targets?
ADMET	Is its pharmacological profile acceptable?
PK	Can useful exposure be achieved?
Toxicity	Are major liabilities predicted?
Synthesis	Can it actually be manufactured?
Novelty	Does it provide meaningful chemical differentiation?

This is where a seemingly excellent AI-generated molecule can fail.

And failure is valuable.

A mature discovery system should treat failed candidates as information, not wasted computation.

05 — The Scientific Multi-Agent Council

A single AI model may produce a coherent answer.

That does not necessarily make the answer scientifically reliable.

The architecture therefore introduces specialized virtual scientific roles.

🧪 Computational Biochemist

Responsible for:

docking
molecular interactions
molecular dynamics
target selectivity

⚗️ Medicinal Chemist

Responsible for:

SAR
molecular optimization
chemical tractability
retrosynthetic analysis

💊 Clinical Pharmacologist

Responsible for:

PK/PD
exposure
half-life
toxicity
drug–drug interactions

Future versions could add:

Toxicologist
Structural Biologist
Bioinformatician
Clinical Scientist
Regulatory Scientist

The objective is not to create fictional scientists.

It is to create independent analytical perspectives with explicit responsibilities.

06 — Scientific Arbitration

This is arguably the most important architectural component.

Suppose the molecular-design agent proposes:

Binding Energy: −9.8 kcal/mol

That looks excellent.

But another agent identifies:

LogP: 5.2

and predicts poor pharmacokinetic behavior.

Which agent is correct?

The answer should not be determined by whichever model generated the most convincing paragraph.

Instead, the system should perform:

Agent A
   ↓
Agent B
   ↓
Agent C
   ↓
Contradiction Detection
   ↓
Evidence Arbitration
   ↓
Candidate Re-ranking

The critic therefore becomes a Scientific Arbitration Engine.

Its job is to:

detect contradictions;
challenge unsupported assumptions;
compare evidence;
quantify uncertainty;
request additional computation or experiments;
reject weak candidates;
synthesize defensible conclusions.

07 — Closed-Loop Experimental Learning

This is where the architecture moves beyond prompt engineering.

AI cannot validate a drug purely by generating text.

The ultimate loop must connect computational intelligence to physical experimentation:

AI Hypothesis
     ↓
Candidate Design
     ↓
Virtual Screening
     ↓
Synthesis Planning
     ↓
Laboratory Experiment
     ↓
Assay Results
     ↓
Experimental Data
     ↓
Model Update
     ↓
Candidate Redesign
     ↺

This creates a fundamentally different paradigm:

AI → Experiment → Learning → AI

The laboratory becomes part of the intelligence loop.

🫁 IPF: A Real-World Reference Case

Idiopathic Pulmonary Fibrosis provides a particularly interesting test case.

IPF is a progressive fibrotic lung disease with substantial unmet medical need.

In the Insilico Medicine program, AI-driven biological analysis identified TNIK as a potential therapeutic target.

Generative chemistry was subsequently used to develop rentosertib (ISM001-055), a TNIK inhibitor.

The program progressed into human clinical testing and eventually reached a randomized Phase 2a study.

The reported results included a mean FVC change of:

+98.4 mL

for patients receiving 60 mg rentosertib once daily, compared with:

−20.3 mL

for placebo.

In patients not receiving standard-of-care therapy, the reported change was:

+187.8 mL

These findings are highly interesting.

But scientific precision matters.

A 12-week Phase 2a result should not automatically be described as proof of reversal of pulmonary fibrosis.

A better interpretation is:

The study provides preliminary evidence of a potentially meaningful improvement in lung-function trajectory that requires confirmation in larger and longer clinical trials.

That distinction is critical.

⚠️ What Rentosertib Does — and Does Not — Prove

There is an important methodological distinction.

The rentosertib program provides evidence that AI-native drug discovery can progress from computational discovery into clinical development.

It does not prove that the exact ten-prompt-framework architecture described here was responsible for discovering rentosertib.

Therefore, the appropriate scientific relationship is:

Rentosertib
     ↓
Empirical Reference Case
     ↓
Demonstrates feasibility of AI-native discovery

Cognitive-Augmented Architecture
     ↓
Proposed Orchestration Framework
     ↓
Requires independent benchmarking

This distinction prevents the architecture from making a post-hoc causal claim that the available evidence does not establish.

🎯 The Missing Dimension: Uncertainty

One of the biggest challenges in AI-driven science is that predictions are probabilistic.

A mature system should not simply output:

Affinity = 0.87

It should attempt to represent:

Prediction
   +
Confidence
   +
Uncertainty
   +
Evidence Provenance

The system should also maintain:

model version
dataset provenance
computational parameters
experimental history
decision history
conflicting evidence

This creates something more valuable than a chatbot answer:

An auditable scientific decision process.

Importantly, auditability should come from provenance, reproducibility and evidence tracking, rather than assuming that exposing a model's chain-of-thought automatically provides trustworthy reasoning.

🔬 How Do We Prove the Architecture Works?

This is where the concept becomes a research program.

We should not simply claim that multi-agent cognitive orchestration is better.

We should test it.

Baseline 1

Single AI agent

Baseline 2

Single agent + structured prompting

Baseline 3

Multi-agent system

Baseline 4

Multi-agent + Scientific Critic

Baseline 5

Multi-agent + Critic + Experimental Feedback

Then measure:

target-ranking accuracy
molecular validity
novelty
affinity
selectivity
ADMET
synthetic feasibility
experimental hit rate
false-positive rate
time-to-PCC
computational cost
expert acceptance

This creates an ablation framework for cognitive orchestration.

📊 The New Benchmark

The most important question is no longer:

“Can AI generate a molecule?”

AI can already generate molecules.

The harder question is:

Can an AI orchestration system consistently transform hypotheses into experimentally validated candidates faster, more efficiently and more reproducibly than conventional workflows?

That is the benchmark that matters.

🚀 Beyond “Prompt-to-Drug”

“Prompt-to-Drug” is an attractive phrase.

But technically, a prompt does not create a drug.

The real pipeline is:

Prompt
   ↓
Scientific Orchestration
   ↓
Hypothesis
   ↓
Computational Validation
   ↓
Experiment
   ↓
Evidence
   ↓
Learning
   ↓
Optimization
   ↓
Clinical Development

So the more precise concept is:

Prompt-to-Drug Orchestration

The LLM is not the laboratory.

It is not the medicinal chemist.

It is not the clinical trial.

It is the cognitive coordination layer connecting specialized scientific capabilities.

🌐 From AI-Assisted to AI-Native Science

The pharmaceutical AI stack is evolving.

Generation

AI creates candidates.

↓

Prediction

AI estimates properties.

↓

Orchestration

AI coordinates specialized systems.

↓

Experimentation

AI-guided hypotheses are physically tested.

↓

Learning

Experimental evidence updates the system.

↓

Autonomous Iteration

The next hypothesis is generated from what was learned.

This is the transition from:

AI-assisted drug discovery

to:

AI-native scientific discovery

🧠 The Bigger Idea

The future of AI drug discovery may not be determined by who has the largest model.

It may be determined by who builds the best scientific feedback architecture.

The winning system could combine:

Foundation Models

Specialized Scientific Agents

Computational Chemistry

Biological Intelligence

Robotic Laboratories

Evidence Provenance

Uncertainty Estimation

Human Scientific Oversight

Together, these components create something fundamentally different from an LLM chatbot.

They create a system capable of:

forming hypotheses → challenging hypotheses → testing hypotheses → learning from failure → generating better hypotheses.

That is the real promise of Cognitive-Augmented AI.

🔮 Final Question

The most important question for the next decade of pharmaceutical AI may not be:

How intelligent is the model?

It may be:

How effectively can the system transform intelligence into experimentally validated knowledge?

That is the real journey:

Prompt → Hypothesis → Experiment → Evidence → Learning → Drug

And perhaps the ultimate architecture of AI-driven science will not be a better chatbot.

It will be a closed-loop scientific intelligence system.

References

Xu et al. (2025), A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial, Nature Medicine.
Insilico Medicine — AI-driven drug discovery programs.
IQVIA Institute — Global R&D Trends 2026.
Deloitte — Annual Biopharma Innovation Report.
Tufts Center for the Study of Drug Development — Drug Development Cost Studies.